NOVO-DIFLUNISAL TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DIFLUNISAL

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

N02BA11

SNN (starptautisko nepatentēto nosaukumu):

DIFLUNISAL

Deva:

500MG

Zāļu forma:

TABLET

Kompozīcija:

DIFLUNISAL 500MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

60/100/500

Receptes veids:

Prescription

Ārstniecības joma:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0113161002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2018-04-30

Produkta apraksts

PRODUCT MONOGRAPH
NOVO-DIFLUNISAL
(diflunisal)
Film-coated Tablets 250 and 500 mg
THERAPEUTIC CLASSIFICATION
Analgesic, Anti-Inflammatory Agent
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
June 19, 2014
Toronto ON
M1B 2K9
Control # 174380
2
NAME OF DRUG
Novo-DIFLUNISAL
(diflunisal tablets, USP)
250 and 500 mg
THERAPEUTIC CLASSIFICATION
Anti-Inflammnatory, Analgesic Agent
ACTION AND CLINICAL PHARMACOLOGY
Diflunisal is a non-steroidal drug with analgesic, anti- inflammatory
and antipyretic
properties. The precise mechanism of the analgesic and
anti-inflammatory actions of
diflunisal is not known, however, it appears to be a
peripherally-acting analgesic drug.
Diflunisal is a prostaglandin synthetase inhibitor. In animals,
prostaglandins sensitize
afferent nerves and potentiate the action of bradykinin in inducing
pain. Since
prostaglandins are known to be among the mediators of pain and
inflammation, the mode
of action of diflunisal may be due in part to a decrease of
prostaglandins in peripheral
tissues.
Pharmacokinetics and Metabolism
Diflunisal is rapidly and completely absorbed following oral
administration with peak
plasma concentrations occurring between 2 to 3 hours. The drug is
excreted in the urine
as two soluble glucuronide conjugates accounting for about 90% of the
administered
dose. Little or no diflunisal is excreted in the feces. Diflunisal
appears in human milk in
concentrations of 2 - 7% of those in plasma. More than 99% of
diflunisal in plasma is
bound to proteins.
As is the case with salicylic acid, concentration-dependent
pharmacokinetics prevail
when diflunisal is administered; a doubling of dosage produces a
greater than doubling of
drug accumulation.
The effect becomes more apparent with repetitive doses. Following
single doses, peak
plasma concentrations of 41 ± 11 µg/mL (mean ± S.D.) were observed
following 250 mg
3
doses 87 ± 17 µg/mL were observed following 500 mg and 124 ± 11
µg/mL following
single 1000 mg doses. However, following administration of 250 mg
b.i.d., a